Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Van Hemelrijck M, et al. Among authors: van der linden w. Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29. Eur Urol. 2019. PMID: 30385049 Free PMC article.
Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.
van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium; Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J. van der Kwast TH, et al. Among authors: van hemelrijck m, van der kwast t, van bochove k, van der linden w. Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13. Eur Urol Oncol. 2019. PMID: 31200849
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Kalapara AA, et al. Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26. Eur Urol Oncol. 2020. PMID: 31564531
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Bruinsma SM, Nieboer D, Roobol MJ, Bangma CH, Verbeek JFM, Gnanapragasam V, Van Hemelrijck M, Frydenberg M, Lee LS, Valdagni R, Logothetis C, Steyerberg EW; the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Bruinsma SM, et al. J Urol. 2021 Jul;206(1):62-68. doi: 10.1097/JU.0000000000001700. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617330
A first step towards a global nomogram to predict disease progression for men on active surveillance.
Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, Nieboer D, Bangma C, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam V, Kattan MW; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Van Hemelrijck M, et al. Transl Androl Urol. 2021 Mar;10(3):1102-1109. doi: 10.21037/tau-20-1082. Transl Androl Urol. 2021. PMID: 33850745 Free PMC article.
Using the Movember Foundation's GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function-a retrospective study in low-risk prostate cancer patients.
Crump RT, Remmers S, Van Hemelrijck M, Helleman J, Nieboer D, Roobol MJ, Venderbos LDF; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Crump RT, et al. Transl Androl Urol. 2021 Jun;10(6):2719-2727. doi: 10.21037/tau-20-1255. Transl Androl Urol. 2021. PMID: 34295757 Free PMC article.
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database.
Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Beckmann K, et al. Eur Urol Open Sci. 2021 Nov 1;34:47-54. doi: 10.1016/j.euros.2021.09.012. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34934967 Free PMC article.
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.
Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium. Olivier J, et al. Eur Urol Open Sci. 2022 Jan 3;35:59-67. doi: 10.1016/j.euros.2021.11.006. eCollection 2022 Jan. Eur Urol Open Sci. 2022. PMID: 35024633 Free PMC article.
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Remmers S, et al. Eur Urol Open Sci. 2022 Jun 14;41:126-133. doi: 10.1016/j.euros.2022.05.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813247 Free PMC article.
207 results